Xeris Pharmaceuticals (NASDAQ:XERS) Shares Up 6%

Xeris Pharmaceuticals Inc (NASDAQ:XERS) shares shot up 6% during trading on Thursday . The stock traded as high as $9.14 and last traded at $9.00, 120,840 shares were traded during mid-day trading. A decline of 42% from the average session volume of 209,008 shares. The stock had previously closed at $8.49.

Several brokerages recently commented on XERS. Mizuho reiterated a “buy” rating and issued a $27.00 target price on shares of Xeris Pharmaceuticals in a report on Tuesday, September 10th. ValuEngine downgraded shares of Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, September 30th. Finally, Royal Bank of Canada set a $18.00 target price on shares of Xeris Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th.

The stock has a market cap of $207.80 million, a P/E ratio of -1.80 and a beta of -0.44. The company has a current ratio of 6.00, a quick ratio of 6.00 and a debt-to-equity ratio of 0.39. The firm’s fifty day moving average is $9.83 and its 200 day moving average is $10.65.

Xeris Pharmaceuticals (NASDAQ:XERS) last announced its earnings results on Tuesday, August 6th. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.34). The firm had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 107.65% and a negative net margin of 4,876.50%. Research analysts forecast that Xeris Pharmaceuticals Inc will post -4.74 earnings per share for the current fiscal year.

In other Xeris Pharmaceuticals news, insider Steven Prestrelski sold 27,700 shares of the firm’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $9.00, for a total value of $249,300.00. Company insiders own 7.43% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC grew its position in Xeris Pharmaceuticals by 2.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 54,773 shares of the company’s stock worth $627,000 after purchasing an additional 1,434 shares during the last quarter. Bank of Montreal Can acquired a new stake in Xeris Pharmaceuticals in the 2nd quarter worth $26,000. Tower Research Capital LLC TRC acquired a new stake in Xeris Pharmaceuticals in the 2nd quarter worth $42,000. Marshall Wace North America L.P. acquired a new stake in Xeris Pharmaceuticals in the 1st quarter worth $71,000. Finally, Northern Trust Corp grew its position in Xeris Pharmaceuticals by 3.8% in the 2nd quarter. Northern Trust Corp now owns 249,214 shares of the company’s stock worth $2,851,000 after purchasing an additional 9,188 shares during the last quarter. Institutional investors own 62.44% of the company’s stock.

Xeris Pharmaceuticals Company Profile (NASDAQ:XERS)

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Read More: Buyback

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.